On September 27, 2013, national headlines were filled with news about a recent advancement in the treatment of diabetes. It was an advancement that those in the healthcare industry have been fervently working on for years. The diabetes treatment making all of the recent headlines is Medtronic’s APDS, also known as the MiniMed530G. It is an artificial pancreas device system that the company finally received partial U.S. FDA approval on in September. The approval enables the system to be used with adult populations. The company is hoping to expand upon that approval in the future to include juveniles under the age of 16. At this point, the product itself is anticipated to be available for purchase in the coming weeks. The company’s new system consists of a CGM integrated insulin pump that has been outfitted with a hypersensitive glucose sensor, bolus wizard, automatic alerts and a preset, threshold suspension feature. Because of those features, it is said to be helpful…